Abstract
Patients with hepatocellular carcinoma (HCC) may be eligible for liver transplantation. Liver transplant candidates with HCC compete for the same deceased donor organs as those without HCC. These scarce organs must be allocated fairly and justly to those who will benefit most. Unlike most other cancers, HCC is often diagnosed noninvasively by imaging without biopsy confirmation. Therefore, radiologists play an important role in diagnosing definite HCC (i.e., LR-5 category) that counts toward staging and determination of liver transplant eligibility. This review explains the conversion of LI-RADS observation categories to organ procurement and transplantation network classes, illustrates the radiologic T-staging systems, reviews selection criteria for liver transplant eligibility, and discusses prioritization of liver transplant candidates with HCC. In addition, this review summarizes imaging requirements, including contrast agents accepted, minimum specifications for dynamic CT or MRI of the liver, and modalities accepted for assessment of extrahepatic spread or metastatic disease in liver transplant candidates with HCC.
Similar content being viewed by others
Abbreviations
- AASLD:
-
American Association for the Study of Liver Diseases
- ALTS:
-
American Liver Tumor Study Group
- BCLC:
-
Barcelona Clinic Liver Cancer
- HCC:
-
Hepatocellular Carcinoma
- LI-RADS:
-
Liver Imaging Reporting and Data System
- UNOS:
-
United Network for Organ Sharing
- OPTN:
-
Organ Procurement and Transplantation Network
References
OPTN/UNOS policy 9: Allocation of livers and liver-intestines. http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf-nameddest=Policy_09. Accessed 4 March 2017
Park JW, Chen M, Colombo M, et al. (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35(9):2155–2166. doi:10.1111/liv.12818
Wald C (2014) A prospective, multicenter comparison of multiphase contrast-enhanced CT and multiphase contrast-enhanced MRI for diagnosis of hepatocellular carcinoma and liver transplant allocation https://www.acrin.org/Portals/0/Protocols/6690/ACRIN6690_Amend4_v022414-ForOnline.pdf
Norris S (2011) Organ donation and transplantation in Canada. Library of Parliament
Mazzaferro V, Regalia E, Doci R, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699. doi:10.1056/NEJM199603143341104
Silva MF, Sherman M (2011) Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 55(5):1137–1147. doi:10.1016/j.jhep.2011.05.012
Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382. doi:10.1148/radiol.12121698
Duffy JP, Vardanian A, Benjamin E, et al. (2007) Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246(3):502–509 (discussion 509–511). doi:10.1097/SLA.0b013e318148c704
Guiteau JJ, Cotton RT, Washburn WK, et al. (2010) An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant 10(9):2092–2098. doi:10.1111/j.1600-6143.2010.03222.x
Yao FY, Ferrell L, Bass NM, et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403. doi:10.1053/jhep.2001.24563
Yao FY (2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8(10):1982–1989. doi:10.1111/j.1600-6143.2008.02351.x
Hayashi PH, Trotter JF, Forman L, et al. (2004) Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 10(1):42–48. doi:10.1002/lt.20020
Pomfret EA, Washburn K, Wald C, et al. (2010) Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplant 16(3):262–278. doi:10.1002/lt.21999
OPTN/UNOS policy 3.6.6. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf
Rockey DC, Caldwell SH, Goodman ZD, et al. (2009) Liver biopsy. Hepatology 49(3):1017–1044. doi:10.1002/hep.22742
Caturelli E, Solmi L, Anti M, et al. (2004) Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 53(9):1356–1362. doi:10.1136/gut.2003.032359
Scholmerich J, Schacherer D (2004) Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut 53(9):1224–1226. doi:10.1136/gut.2004.040816
Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104. doi:10.1002/hep.21966
Bret PM, Labadie M, Bretagnolle M, et al. (1988) Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol 13(3):253–255
Giorgio A, Tarantino L, de Stefano G, et al. (2003) Complications after interventional sonography of focal liver lesions: a 22-year single-center experience. J Ultrasound Med 22(2):193–205
Durand F, Regimbeau JM, Belghiti J, et al. (2001) Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35(2):254–258
Takamori R, Wong LL, Dang C, Wong L (2000) Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transplant 6(1):67–72. doi:10.1002/lt.500060103
Saborido BP, Diaz JC, de Los Galanes SJ, et al. (2005) Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc 37(9):3874–3877. doi:10.1016/j.transproceed.2005.09.169
Fernandez-Salazar L, Velayos B, Aller R, et al. (2011) Percutaneous liver biopsy: patients’ point of view. Scand J Gastroenterol 46(6):727–731. doi:10.3109/00365521.2011.558112
Heimbach J, Kulik LM, Finn R, et al. (2017) Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology . doi:10.1002/hep.29086
American College of Radiology (2017). Liver imaging reporting and data system. http://www.acr.org/quality-safety/resources/LIRADS
Choi SH, Byun JH, Kim SY, et al. (2016) Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51(8):483–490. doi:10.1097/RLI.0000000000000258
Chen N, Motosugi U, Morisaka H, et al. (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15(1):49–59. doi:10.2463/mrms.2014-0149
Darnell A, Forner A, Rimola J, et al. (2015) Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275(3):698–707. doi:10.1148/radiol.15141132
Katyal S, Oliver JH 3rd, Peterson MS, et al. (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216(3):698–703. doi:10.1148/radiology.216.3.r00se24698
Natsuizaka M, Omura T, Akaike T, et al. (2005) Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20(11):1781–1787. doi:10.1111/j.1440-1746.2005.03919.x
Kaczynski J, Hansson G, Wallerstedt S (1995) Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor. An autopsy study from a low endemic area. Acta Oncol 34(1):43–48
Kim WR, Lake JR, Smith JM, et al. (2015) OPTN/SRTR 2013 annual data report: liver. Am J Transplant 15(Suppl 2):1–28. doi:10.1111/ajt.13197
Llovet JM, Mas X, Aponte JJ, et al. (2002) Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50(1):123–128
Yao FY, Kerlan RK Jr, Hirose R, et al. (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48(3):819–827. doi:10.1002/hep.22412
Clavien PA, Lesurtel M, Bossuyt PM, et al. (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13(1):e11–e22. doi:10.1016/S1470-2045(11)70175-9
Acknowledgements
This work was supported by (1) the Fonds de recherche du Québec—Santé (Career Award #26993), and (2) New Researcher Startup Grant from the Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM) to An Tang.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
An Tang: Advisory Board of Imagia Cybernetics. Kathryn J. Fowler and Victoria Chernyak have nothing to disclose. William Chapman: Scientific Advisory Board of Novartis Pharmaceutical. Founder of Pathfinder Therapeutics. Claude B. Sirlin: Industry research grants Bayer, Guerbet, Siemens, GE, Philips, Supersonic, Arterys. Consulting and service agreements Alexion, AstraZeneca, Bioclinica, BMS, Bracco, Celgene, Fibrogen, Galmed, Genentech, Genzyme, Gilead, Icon, Intercept, Isis, Janssen, NuSirt, Perspectum, Pfizer, Profil, Sanofi, Shire, Synageva, Tobira, Takeda, Virtual Scopics.
Rights and permissions
About this article
Cite this article
Tang, A., Fowler, K.J., Chernyak, V. et al. LI-RADS and transplantation for hepatocellular carcinoma. Abdom Radiol 43, 193–202 (2018). https://doi.org/10.1007/s00261-017-1210-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-017-1210-8